Literature DB >> 7795286

Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis.

M Cottone1, A Magliocco, G Trallori, C Brignola, C Vandelli, S Ardizzone, G Meucci, F Zannoni, G Di Maio, M Astegiano.   

Abstract

Seven patients with inactive ulcerative colitis and seven patients with Crohn's disease (5 inactive, 2 mildly active) received interferon treatment for associated chronic active hepatitis. Neither relapse (except in one patient) nor worsening of the clinical course of the inflammatory bowel disease was observed during treatment. According to these results chronic active hepatitis associated with inflammatory bowel disease can be treated with interferon without the risk of deteriorating the course of the inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795286

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  5 in total

Review 1.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

2.  Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital.

Authors:  Yolanda Faia Manhaes Tolentino; Homero Soares Fogaca; Cyrla Zaltman; Lia Laura Lewis Ximenes; Henrique Sergio Moraes Coelho
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

3.  Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.

Authors:  Alina M Allen; W Ray Kim; Joseph Larson; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 4.  Hepatitis C virus and inflammatory bowel disease.

Authors:  Todd L Horn; Joel Reynolds; Willem de Villiers; Luis R Peña
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

5.  Large intestine histopathology of pegylated-interferon-alpha plus ribavirin treated chronic hepatitis C patients.

Authors:  Konstantinos D Pantazis; Ioannis S Elefsiniotis; Dimitrios Papaioannou; Hero Brokalaki; Gerasimos Bonatsos; Christos Mavrogiannis
Journal:  Gastroenterol Res Pract       Date:  2008       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.